Chronic Refractory Cough Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major chronic refractory cough markets reached a value of US$ 9.4 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 14.1 Billion by 2034, exhibiting a growth rate (CAGR) of 3.74% during 2024-2034.
The chronic refractory cough market has been comprehensively analyzed in IMARC's new report titled "Chronic Refractory Cough Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chronic refractory cough (CRC) is a condition in which a person experiences a persistent cough that lasts for more than eight weeks despite undergoing multiple treatments. The disease can significantly affect an individual's quality of life, causing sleep disturbances, fatigue, and social isolation. The main symptom of this illness includes a dry, irritated cough localized around the laryngeal area. Other common indications of CRC involve globus, dyspnea, dysphonia, dizziness, persistent chest pain, night sweats, and physical complications, such as urinary incontinence, fractured ribs, muscle strain, etc. The diagnosis of this condition typically requires the identification of a patient's clinical features, medical history, and physical exam. A blood workup and allergy test can be utilized to evaluate signs of infection or other environmental factors that could be causing underlying symptoms. The healthcare provider may also perform spirometry or pulmonary function tests, which help determine lung functionality by measuring airflow in and out of the lungs. Additionally, laryngeal examination using flexible nasendoscopy, that detects the existence of laryngeal lesions or atypical motor patterns contributing to disease symptoms and laryngeal discomfort, is recommended among patients.
The increasing incidences of respiratory tract disorders secondary to sensory nerve damage caused by viral infections, inflammation, allergic factors, etc., are primarily driving the chronic refractory cough market. Besides this, the rising prevalence of various associated risk factors, including smoking, acid reflux, asthma, exposure to irritants, etc., which can irritate the airways, is also bolstering the market growth. Furthermore, the widespread adoption of neuro-modulating agents, like gabapentin and amitriptyline, since they act on the heightened neural sensitization that is linked with the pathogenesis of CRC, is creating a positive outlook for the market. Apart from this, the escalating utilization of non-pharmacological interventions, such as cough-suppression physiotherapy and speech therapy in patients who have failed or not responded to conventional medicinal regimens, is also augmenting the market growth. Additionally, the emerging popularity of superior laryngeal nerve block as a long-term treatment alternative, owing to its numerous advantages, including high patient compliance, feasibility, safety, and improved quality of life, is further expected to drive the chronic refractory cough market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the chronic refractory cough market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for chronic refractory cough and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chronic refractory cough market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the chronic refractory cough market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the chronic refractory cough market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current chronic refractory cough marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the chronic refractory cough market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the chronic refractory cough market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the chronic refractory cough market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of chronic refractory cough across the seven major markets?
What is the number of prevalent cases (2018-2034) of chronic refractory cough by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of chronic refractory cough by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with chronic refractory cough across the seven major markets?
What is the size of the chronic refractory cough patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of chronic refractory cough?
What will be the growth rate of patients across the seven major markets?
Chronic Refractory Cough: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for chronic refractory cough drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chronic refractory cough market?
What are the key regulatory events related to the chronic refractory cough market?
What is the structure of clinical trial landscape by status related to the chronic refractory cough market?
What is the structure of clinical trial landscape by phase related to the chronic refractory cough market?
What is the structure of clinical trial landscape by route of administration related to the chronic refractory cough market?
The chronic refractory cough market has been comprehensively analyzed in IMARC's new report titled "Chronic Refractory Cough Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chronic refractory cough (CRC) is a condition in which a person experiences a persistent cough that lasts for more than eight weeks despite undergoing multiple treatments. The disease can significantly affect an individual's quality of life, causing sleep disturbances, fatigue, and social isolation. The main symptom of this illness includes a dry, irritated cough localized around the laryngeal area. Other common indications of CRC involve globus, dyspnea, dysphonia, dizziness, persistent chest pain, night sweats, and physical complications, such as urinary incontinence, fractured ribs, muscle strain, etc. The diagnosis of this condition typically requires the identification of a patient's clinical features, medical history, and physical exam. A blood workup and allergy test can be utilized to evaluate signs of infection or other environmental factors that could be causing underlying symptoms. The healthcare provider may also perform spirometry or pulmonary function tests, which help determine lung functionality by measuring airflow in and out of the lungs. Additionally, laryngeal examination using flexible nasendoscopy, that detects the existence of laryngeal lesions or atypical motor patterns contributing to disease symptoms and laryngeal discomfort, is recommended among patients.
The increasing incidences of respiratory tract disorders secondary to sensory nerve damage caused by viral infections, inflammation, allergic factors, etc., are primarily driving the chronic refractory cough market. Besides this, the rising prevalence of various associated risk factors, including smoking, acid reflux, asthma, exposure to irritants, etc., which can irritate the airways, is also bolstering the market growth. Furthermore, the widespread adoption of neuro-modulating agents, like gabapentin and amitriptyline, since they act on the heightened neural sensitization that is linked with the pathogenesis of CRC, is creating a positive outlook for the market. Apart from this, the escalating utilization of non-pharmacological interventions, such as cough-suppression physiotherapy and speech therapy in patients who have failed or not responded to conventional medicinal regimens, is also augmenting the market growth. Additionally, the emerging popularity of superior laryngeal nerve block as a long-term treatment alternative, owing to its numerous advantages, including high patient compliance, feasibility, safety, and improved quality of life, is further expected to drive the chronic refractory cough market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the chronic refractory cough market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for chronic refractory cough and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chronic refractory cough market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the chronic refractory cough market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the chronic refractory cough market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current chronic refractory cough marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the chronic refractory cough market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the chronic refractory cough market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the chronic refractory cough market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of chronic refractory cough across the seven major markets?
What is the number of prevalent cases (2018-2034) of chronic refractory cough by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of chronic refractory cough by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with chronic refractory cough across the seven major markets?
What is the size of the chronic refractory cough patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of chronic refractory cough?
What will be the growth rate of patients across the seven major markets?
Chronic Refractory Cough: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for chronic refractory cough drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chronic refractory cough market?
What are the key regulatory events related to the chronic refractory cough market?
What is the structure of clinical trial landscape by status related to the chronic refractory cough market?
What is the structure of clinical trial landscape by phase related to the chronic refractory cough market?
What is the structure of clinical trial landscape by route of administration related to the chronic refractory cough market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CHRONIC REFRACTORY COUGH - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 CHRONIC REFRACTORY COUGH - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CHRONIC REFRACTORY COUGH - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 CHRONIC REFRACTORY COUGH - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CHRONIC REFRACTORY COUGH - UNMET NEEDS
10 CHRONIC REFRACTORY COUGH - KEY ENDPOINTS OF TREATMENT
11 CHRONIC REFRACTORY COUGH - MARKETED PRODUCTS
11.1 List of Chronic Refractory Cough Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 CHRONIC REFRACTORY COUGH - PIPELINE DRUGS
12.1 List of Chronic Refractory Cough Pipeline Drugs Across the Top 7 Markets
12.1.1 BLU 5937- Bellus Health
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Gefapixant - Merck & Co
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 BAY1817080 - Bayer
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 S-600918 - Shionogi
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 AX8 - Axalbion
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. CHRONIC REFRACTORY COUGH - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. CHRONIC REFRACTORY COUGH – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CHRONIC REFRACTORY COUGH - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Chronic Refractory Cough - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Chronic Refractory Cough - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Chronic Refractory Cough - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Chronic Refractory Cough - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Chronic Refractory Cough - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Chronic Refractory Cough - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Chronic Refractory Cough - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Chronic Refractory Cough - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Chronic Refractory Cough - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Chronic Refractory Cough - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Chronic Refractory Cough - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Chronic Refractory Cough - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Chronic Refractory Cough - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Chronic Refractory Cough - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Chronic Refractory Cough - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Chronic Refractory Cough - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Chronic Refractory Cough - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Chronic Refractory Cough - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Chronic Refractory Cough - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Chronic Refractory Cough - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Chronic Refractory Cough - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Chronic Refractory Cough - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Chronic Refractory Cough - Access and Reimbursement Overview
16 CHRONIC REFRACTORY COUGH - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CHRONIC REFRACTORY COUGH MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CHRONIC REFRACTORY COUGH MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 CHRONIC REFRACTORY COUGH - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 CHRONIC REFRACTORY COUGH - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 CHRONIC REFRACTORY COUGH - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 CHRONIC REFRACTORY COUGH - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 CHRONIC REFRACTORY COUGH - UNMET NEEDS
10 CHRONIC REFRACTORY COUGH - KEY ENDPOINTS OF TREATMENT
11 CHRONIC REFRACTORY COUGH - MARKETED PRODUCTS
11.1 List of Chronic Refractory Cough Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 CHRONIC REFRACTORY COUGH - PIPELINE DRUGS
12.1 List of Chronic Refractory Cough Pipeline Drugs Across the Top 7 Markets
12.1.1 BLU 5937- Bellus Health
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Gefapixant - Merck & Co
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 BAY1817080 - Bayer
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 S-600918 - Shionogi
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 AX8 - Axalbion
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. CHRONIC REFRACTORY COUGH - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. CHRONIC REFRACTORY COUGH – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 CHRONIC REFRACTORY COUGH - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Chronic Refractory Cough - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Chronic Refractory Cough - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Chronic Refractory Cough - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Chronic Refractory Cough - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Chronic Refractory Cough - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Chronic Refractory Cough - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Chronic Refractory Cough - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Chronic Refractory Cough - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Chronic Refractory Cough - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Chronic Refractory Cough - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Chronic Refractory Cough - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Chronic Refractory Cough - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Chronic Refractory Cough - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Chronic Refractory Cough - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Chronic Refractory Cough - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Chronic Refractory Cough - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Chronic Refractory Cough - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Chronic Refractory Cough - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Chronic Refractory Cough - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Chronic Refractory Cough - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Chronic Refractory Cough - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Chronic Refractory Cough - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Chronic Refractory Cough - Access and Reimbursement Overview
16 CHRONIC REFRACTORY COUGH - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 CHRONIC REFRACTORY COUGH MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 CHRONIC REFRACTORY COUGH MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
